In Preliminary Recommendation, UK's NICE Backs Oncotype DX in Subset of Breast Cancer Patients
February 20, 2013
In Preliminary Recommendation, UK's NICE Backs Oncotype DX in Subset of Breast Cancer Patients
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Breast Cancer Test Makers Will Attempt to Sway UK's NICE in Wake of Initial Negative Opinion
February 8, 2012 / Pharmacogenomics Reporter - Economic Model Finds MammaPrint More Cost-Effective than Oncotype; Highlights Need for Future Studies
May 9, 2012 / Pharmacogenomics Reporter - After Moving MammaPrint to FFPE Format, Agendia Sees Revenue Boost, Increasing Adoption
April 25, 2012 / Pharmacogenomics Reporter - St. Gallen Experts Recommend Oncotype DX for Chemoprediction; Support Breast Cancer Subtyping
July 27, 2011 / Pharmacogenomics Reporter - Genomic Health Study Highlights Discrepancy between Oncotype DX and MammaPrint Results
December 19, 2012 / Pharmacogenomics Reporter